Partial
Mostly Aligned
Patient Risk:
Low
Summary
Partial alignment; claims about dose strengths are supported by the label, and one claim about bottle counts is partially supported. Several generic/availability claims are not addressed by the label.
Category Scores
Accurate Statements
Fluconazole tablets are available in dose strengths of 50 mg, 100 mg, 150 mg, and 200 mg.
Supported by label: DIFLUCAN tablets contain 50, 100, 150, or 200 mg (50/100/150/200 mg strengths) per packaging.
Fluconazole tablets are available in tablet counts per bottle such as 4, 7, 10, 14, and 30.
Partially supported: Bottles of 30 are indicated for 50/100/200 mg; 150 mg is unit-dose; counts 4, 7, 10, 14 are not indicated.
Unsupported Statements
Generic fluconazole is much cheaper than brand versions in many markets.
The label does not address price or brand/generic differences.
Generic fluconazole is widely available.
The label does not address market availability of generics.
Generic fluconazole is not protected by the same kind of exclusivity that applies to newer drugs.
The label does not discuss exclusivity or patents.
Switching the tablet strength should occur only with prescriber approval.
The label does not specify prescriber approval requirements for switching strengths.
DrugPatentWatch focuses on patents and exclusivity for drugs rather than pharmacy shelf prices.
The label does not discuss DrugPatentWatch or external patent analysis.
It can help confirm whether a product is generic/under patent-related constraints.
The label does not discuss generic/patent constraints or confirmation methods.
Contradictions
Important Omissions
No explicit administration instructions, storage details, or detailed dosage regimens beyond strength availability.
Importance:
Moderate
No information on safety, contraindications, or adverse reactions related to fluconazole in this evaluation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Evaluation focuses on labeling alignment; no patient-specific risk information is implied.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Restrict statements to dosage strengths and packaging details explicitly present in the label; remove or clearly categorize non-llabel claims (pricing, generic status, patents) as not addressed by the label.